Cefadroxil_50370-12-2_DataSheet_MedChemExpress
Diva Decloaker 10X Pretreatment Reagent 说明书
Intended Use:For In Vitro Diagnostic UseHeat induced antigen retrieval of formalin-fixed paraffin-embedded (FFPE) tissues for immunohistochemistry (IHC) procedures. The clinical interpretation of any staining or its absence should be complimented by morphological studies using proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.Summary & Explanation:Diva Decloaker is a heat retrieval solution that is compatible with virtually all antibodies and eliminates the need for multiple buffers including citrate buffer, EDTA or high pH tris buffers. Antibody titers are doubled and tripled when compared to citrate buffer, pH 6.0. Diva Decloaker incorporates Assure™ tech nology, a color-coded high temperatures pH indicator solution. The end-user is assured by visual inspection that the solution is at the correct dilution and pH. This product is specially formulated for superior pH stability at high temperatures and will help prevent the possibility of losing pH sensitive antigens. Diva Decloaker is non-toxic, non-flammable, odorless and sodium azide and thimerosal free.Known Applications:Immunohistochemistry (formalin-fixed paraffin-embedded tissues) Supplied As:100mlDiva Decloaker, 10X concentrate (DV2004LX)500mlDiva Decloaker, 10X concentrate (DV2004MX)Materials and Reagents (Needed But Not Provided): Microscope slides, positively chargedDesert Chamber* (Drying oven)Positive and negative tissue controlsXylene (Could be substituted with xylene substitute*)Ethanol or reagent alcoholDecloaking Chamber* (Pressure cooker)Deionized or distilled waterWash buffer*(TBS/PBS)Enzyme digestion*Avidin-Biotin Blocking Kit*(Labeled Streptavidin Kits Only) Peroxidase block*Protein block*Primary antibody*Negative control reagents*Detection kits*Detection components*Chromogens*Hematoxylin*Bluing reagent*Mounting medium** Biocare Medical Products: Refer to a Biocare Medical catalog for further information regarding catalog number and ordering information. Certain reagents listed above are based on specific application and detection system used. Storage and Stability:Store at room temperature. Do not use after expiration date printed on vial. If reagents are stored under conditions other than those specified in the package insert, they must be verified by the user. Diluted reagents should be used promptly; any remaining reagent should be stored at room temperature.Protocol Recommendations:1. Deparaffinize tissues and hydrate to water. If necessary, block for endogenous peroxidase and wash in DI water.2. Dilute concentrated Diva Decloaker at a ratio of 1:10 (1 ml Diva to 9 ml of deionized water).3. Place slides into 1X retrieval solution in a slide container (e.g. Coplin Jar, Tissue -Tek™ staining dish or metal slide canister).4. Retrieve sections under pressure using Biocare's Decloaking Chamber. Follow the recommendations on the antibody data sheet and Decloaking Chamber User Manual.5. Check solution for appropriate color change. (See Technical Note #1)6. Gently rinse by gradually adding DI water to the solution, then remove slides and rinse with DI water.Technical Notes:1. Concentrated Diva Decloaker is a bright yellow color. RTU or 1X solution is a pale yellow color. When the solution reaches 80-125°C, the solution turns yellow and indicates that the high temperature solution is at correct pH. Should the pH rise above 7.0, the solution turns a fuschia red color. Should the pH drop too low, thesolution turns a pink color.2. If using Biocare’s Desert Chamber Pro (a programmable turbo-action drying oven), dry sections at 25ºC overnight or at 37ºC for 30-60 minutes and then dry slides at 60ºC for 30 minutes.3. Use positive char ged slides (use Biocare’s Kling-On HIER Slides) and cut tissues at 4-5 microns. Do not use any adhesives in the water bath. Poor fixation and processing of tissues will cause tissue sections to fall off the slides, especially fatty tissues such as breast. Tissues should be fixed a minimum of 6-12 hours.4. Protocol time and temperatures for HIER can vary depending on the Decloaking Chamber model used. Please refer to the relevant Decloaking Chamber manual for appropriate protocol times and temperatures.Limitations:The protocols for a specific application can vary. These include, but are not limited to: fixation, heat-retrieval method, incubation times, tissue section thickness and detection kit used. Due to the superior sensitivity of these unique reagents, the recommended incubation times and titers listed are not applicable to other detection systems, asresults may vary. The data sheet recommendations and protocols are based on exclusive use of Biocare products. Ultimately, it is the responsibility of the investigator to determine optimal conditions. The clinical interpretation of any positive or negative staining should be evaluated within the context of clinical presentation, morphology and other histopathological criteria by a qualified pathologist. The clinical interpretation of any positive or negative staining should be complemented by morphological studies using proper positive and negative internal and external controls as well as other diagnostic tests.Catalog Number: DV2004 LX, MX Description: 100, 500 ml, concentrateQuality Control:Refer to CLSI Quality Standards for Design and Implementation of Immunohistochemistry Assays; Approved Guideline-Second edition (I/LA28-A2). CLSI Wayne, PA, USA (). 2011 Precautions:1. This product is not classified as hazardous. The preservative used in this reagent is Proclin 300 and the concentration is less than 0.25%. Overexposure to Proclin 300 can cause skin and eye irritation and irritation to mucous membranes and upper respiratory tract. The concentration of Proclin 300 in this product does not meet the OSHA criteria for a hazardous substance. Wear disposable gloves when handling reagents.2. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come in contact with sensitive areas, wash with copious amounts of water.3. Microbial contamination of reagents may result in an increase in nonspecific staining.4. Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change.5. Do not use reagent after the expiration date printed on the vial.6. The SDS is available upon request and is located at /.7. Consult OSHA, federal, state or local regulations for disposal of any toxic substances. Proclin is a trademark of Rohm and Haas Company, or of its subsidiaries or affiliates.Troubleshooting:Follow the antibody specific protocol recommendations according to data sheet provided. If atypical results occur, contact Biocare's Technical Support at 1-800-542-2002.。
Trigonox B（滴苷但羊水）产品数据表单说明书
Product Data SheetTrigonox BDi-tert-butyl peroxideTrigonox® B is a pure peroxide in liquid form.CAS number110-05-4EINECS/ELINCS No. 203-733-6TSCA statuslisted on inventory Molecular weight 146.2Active oxygen contentperoxide10.94%SpecificationsAppearance Clear liquidAssay≥ 99.0 %ApplicationsTrigonox® B (Di-tert-butyl peroxide) can be used for the market segments: polymer production, polymer crosslinking and acrylics production with their different applications/functions. For more information please check our website and/or contact us.Half-life dataThe reactivity of an organic peroxide is usually given by its half-life (t½) at various temperatures. For Trigonox® B in chlorobenzene half-life at other temperatures can be calculated by using the equations and constants mentioned below:0.1 hr at 164°C (327°F)1 hr at 141°C (286°F)10 hr at 121°C (250°F)Formula 1kd = A·e-Ea/RTFormula 2t½ = (ln2)/kdEa153.46 kJ/moleA 4.20E+15 s-1R8.3142 J/mole·KT(273.15+°C) KThermal stabilityOrganic peroxides are thermally unstable substances which may undergo self-accelerating decomposition. The lowest temperature at which self-accelerating decomposition may occur with a substance in the packaging as used for transport is the Self-Accelerating Decomposition Temperature (SADT). The SADT is determined on the basis of the Heat Accumulation Storage Test.SADT80°C (176°F)Method The Heat Accumulation Storage Test is a recognized test method for thedetermination of the SADT of organic peroxides (see Recommendations on theTransport of Dangerous Goods, Manual of Tests and Criteria - United Nations, NewYork and Geneva).StorageDue to the relatively unstable nature of organic peroxides, a loss of quality will occur over a period of time. To minimize the loss of quality, Nouryon recommends a maximum storage temperature (Ts max. ) for each organic peroxide product.Ts Max.40°C (104°F) andTs Min.-30°C (-22°F) to prevent crystallizationNote When stored according to these recommended storage conditions, Trigonox® Bwill remain within the Nouryon specifications for a period of at least 6 months afterdelivery.Packaging and transportIn North America Trigonox® B is packed in non-returnable, five gallon polyethylene containers of 30 lb net weight and steel drums of 100 or 340 lb net weight. In other regions the standard packaging is a 30-liter HDPE can (Nourytainer®) for 20 kg peroxide. Delivery in a 200 l steel drum for 150 kg peroxide is also possible in a number of countries. Both packaging and transport meet the international regulations. For the availability of other packed quantities consult your Nouryon representative. Trigonox® B is classified as Organic peroxide type E; liquid, Division 5. 2; UN 3107.Safety and handlingKeep containers tightly closed. Store and handle Trigonox® B in a dry well-ventilated place away from sources of heat or ignition and direct sunlight. Never weigh out in the storage room. Avoid contact with reducing agents (e. g. amines), acids, alkalis and heavy metal compounds (e. g. accelerators, driers and metal soaps). Please refer to the Safety Data Sheet (SDS) for detailed information on the safe storage, use and handling of Trigonox® B. This information should be thoroughly reviewed prior to acceptance of this product. The SDS is available at /sds-search.Major decomposition productsAcetone, Methane, tert-ButanolAll information concerning this product and/or suggestions for handling and use contained herein are offered in good faith and are believed to be reliable.Nouryon, however, makes no warranty as to accuracy and/or sufficiency of such information and/or suggestions, as to the product's merchantability or fitness for any particular purpose, or that any suggested use will not infringe any patent. Nouryon does not accept any liability whatsoever arising out of the use of or reliance on this information, or out of the use or the performance of the product. Nothing contained herein shall be construed as granting or extending any license under any patent. Customer must determine for himself, by preliminary tests or otherwise, the suitability of this product for his purposes.The information contained herein supersedes all previously issued information on the subject matter covered. The customer may forward, distribute, and/or photocopy this document only if unaltered and complete, including all of its headers and footers, and should refrain from any unauthorized use. Don’t copythis document to a website.Trigonox® and Nourytainer are registered trademarks of Nouryon Functional Chemicals B.V. or affiliates in one or more territories.Contact UsPolymer Specialties Americas************************Polymer Specialties Europe, Middle East, India and Africa*************************Polymer Specialties Asia Pacific************************2022-6-30© 2022Polymer crosslinking Trigonox B。
PCR试剂盒类型
微生物检测试剂盒项目核酸 种类产品编号 产品名称方 法规 格 价 格沙门氏菌 DNASA-6131 沙门氏菌(Spp)核酸检测试剂盒PCR-荧光探针法 40份/盒2400 SA-6132 沙门氏菌(Spp)核酸检测试剂盒 常规PCR40份/盒2000 副溶血性弧菌 DNASA-7051副溶血性弧菌(VP)核酸检测试剂盒PCR-荧光探针法 40份/盒2400 SA-7052副溶血性弧菌(VP)核酸检测试剂盒 常规PCR40份/盒2000 霍乱弧菌 DNASA-7061 霍乱弧菌(VC)核酸检测试剂盒PCR-荧光探针法 40份/盒2400 SA-7062 霍乱弧菌(VC)核酸检测试剂盒 常规PCR40份/盒2000 大肠杆菌 DNASA-7071大肠杆菌(O157:H7)核酸检测试剂盒PCR-荧光探针法 40份/盒2400 SA-7072大肠杆菌(O157:H7)核酸检测试剂盒常规PCR40份/盒2000 单增李斯特菌 DNASA-7081单增李斯特菌(LM)核酸检测试剂盒PCR-荧光探针法 40份/盒2400 SA-7082单增李斯特菌(LM)核酸检测试剂盒常规PCR40份/盒2000 金黄色葡萄球菌 DNASA-7091金黄色葡萄球菌(MRSA)核酸检测试剂盒PCR-荧光探针法 40份/盒2400 SA-7092金黄色葡萄球菌(MRSA)核酸检测试剂盒常规PCR40份/盒2000 口腔变形链球菌 DNASA-7111口腔变形链球菌(SM)核酸检测试剂盒PCR-荧光探针法 40份/盒2400 SA-7112口腔变形链球菌(SM)核酸检测试剂盒常规PCR40份/盒2000 幽门螺旋杆菌 DNASA-7121幽门螺旋杆菌(HP)核酸检测试剂盒PCR-荧光探针法 40份/盒2400 SA-7122幽门螺旋杆菌(HP)核酸检测试剂盒 常规PCR40份/盒2000 乳酸杆菌 DNASA-7131 乳酸杆菌(LB)核酸检测试剂盒PCR-荧光探针法 40份/盒2400 SA-7132 乳酸杆菌(LB)核酸检测试剂盒 常规PCR40份/盒2000 双歧杆菌 DNASA-7141 双歧杆菌(BD)核酸检测试剂盒PCR-荧光探针法 40份/盒 2400 SA-7142 双歧杆菌(BD)核酸检测试剂盒常规PCR 40份/2000盒嗜肺军团杆菌 DNASA-7151 嗜肺军团杆菌(LP)核酸检测试剂盒 PCR-荧光探针法 40份/盒2400SA-7152 嗜肺军团杆菌(LP)核酸检测试剂盒 常规PCR 40份/盒2000空肠弯曲菌 DNA SA-7161 空肠弯曲菌(CJ)核酸检测试剂盒 PCR-荧光探针法 40份/盒2400SA-7162 空肠弯曲菌(CJ)核酸检测试剂盒 常规PCR 40份/盒2000甲型副伤寒沙门氏菌 DNASA-7171 甲型副伤寒沙门氏菌(SPA)核酸检测试剂盒 PCR-荧光探针法 40份/盒2400SA-7172 甲型副伤寒沙门氏菌(SPA)核酸检测试剂盒 常规PCR 40份/盒2000动物检测试剂盒项目 核酸 种类产品编号产品名称 方 法 规 格 价格新城疫 RNASA-6091 新城疫病毒(NDV)核酸检测试剂盒 PCR-荧光探针法 40头份/盒 32SA-6092 新城疫病毒(NDV)核酸检测试剂盒 RT-PCR 法 40头份/盒 28禽流感 RNASA-6011 禽流感病毒通用型(AIV-U)核酸检测试剂盒 PCR-荧光探针法 40头份/盒 32SA-6012 禽流感病毒通用型(AIV-U)核酸检测试剂盒 RT-PCR 法 40头份/盒 28SA-6013 禽流感病毒H5亚型(AIV-H5N1)核酸检测试剂盒 PCR-荧光探针法 40头份/盒 32SA-6014 禽流感病毒H5亚型(AIV-H5N1)核酸检测试剂盒 RT-PCR 法 40头份/盒 28SA-6015 禽流感病毒H7亚型(AIV-H7)核酸检测试剂盒 PCR-荧光探针法 40头份/盒 320 SA-6016 禽流感病毒H7亚型(AIV-H7)核酸检测试剂盒 RT-PCR 法 40头份/盒 28SA-6017 禽流感病毒H9亚型(AIV-H9)核酸检测试剂盒 PCR-荧光探针法 40头份/盒 32SA-6018 禽流感病毒H9亚型(AIV-H9)核酸检测试剂盒 RT-PCR 法 40头份/盒 28SA-6019 禽流感病毒(AIV)基因分型核酸检测试剂盒 多重RT-PCR 法 10头份/盒 16口蹄疫 RNASA-6021 口蹄疫病毒通用型(FMDV-U)核酸检测试剂盒 PCR-荧光探针法 40头份/盒 32SA-6022 口蹄疫病毒通用型(FMDV-U)核酸检测试剂盒 RT-PCR 法 40头份/盒 28SA-6023 口蹄疫病毒Asia-1�型(FMDV-A1)核酸检测试剂盒 PCR-荧光探针法 40头份/盒 32SA-6024 口蹄疫病毒Asia-1�型(FMDV-A1)核酸检测试剂盒 RT-PCR 法 40头份/盒 28SA-6025 口蹄疫病毒O �型(FMDV-O)核酸检测试剂盒 PCR-荧光探针法 40头份/盒 32SA-6026 口蹄疫病毒O �型(FMDV-O)核酸检测试剂盒 RT-PCR 法 40头份/盒 28SA-6027 口蹄疫病毒(FMDV)基因分型核酸检测试剂盒 多重RT-PCR 法 10头份/盒 160 猪蓝耳病 RNASA-6031猪蓝耳病病毒通用型(PRRSV-U)核酸检测试剂盒 PCR-荧光探针法40头份/盒 32SA-6032猪蓝耳病病毒通用型(PRRSV-U)核酸检测试剂盒RT-PCR 法40头份/盒 28SA-6033高致病性猪蓝耳病病毒(PRRSV-M)核酸检测试剂盒 PCR-荧光探针法40头份/盒 32SA-6034高致病性猪蓝耳病病毒(PRRSV-M)核酸检测试剂盒RT-PCR 法40头份/盒 28狂犬病 RNASA-6121 狂犬病毒(RV)核酸检测试剂盒PCR-荧光探针法40头份/盒 32SA-6122 狂犬病毒(RV)核酸检测试剂盒RT-PCR 法40头份/盒 28流行性乙型脑炎RNASA-7011流行性乙型脑炎病毒(JEV)核酸检测试剂盒 PCR-荧光探针法40头份/盒 32SA-7012流行性乙型脑炎病毒(JEV)核酸检测试剂盒RT-PCR 法40头份/盒 28猪瘟 RNASA-6071 猪瘟病毒(CSFV)核酸检测试剂盒PCR-荧光探针法40头份/盒 32SA-6072 猪瘟病毒(CSFV)核酸检测试剂盒RT-PCR 法 40头份/盒 28弓形虫 DNA SA-6051 弓形虫(TOX)核酸检测试剂盒PCR-荧光探针法40头份/盒 240 SA-6052 弓形虫(TOX)核酸检测试剂盒 常规PCR40头份/盒 20布氏杆菌 DNASA-6061 布氏杆菌(BS)核酸检测试剂盒PCR-荧光探针法40头份/盒 24SA-6062 布氏杆菌(BS)核酸检测试剂盒常规PCR40头份/盒 20细小病毒 DNASA-6081 细小病毒(PPV)核酸检测试剂盒PCR-荧光探针法40头份/盒 32SA-6082 细小病毒(PPV)核酸检测试剂盒常规PCR40头份/盒 28伪狂犬 DNASA-6111 伪狂犬病毒(PRV)核酸检测试剂盒PCR-荧光探针法40头份/盒 32SA-6112 伪狂犬病毒(PRV)核酸检测试剂盒常规PCR40头份/盒 28猪疱疹 DNASA-6141 猪疱疹病毒(PHV)核酸检测试剂盒PCR-荧光探针法40头份/盒 24SA-6142 猪疱疹病毒(PHV)核酸检测试剂盒常规PCR40头份/盒 20猪链球菌 DNASA-6041猪链球菌通用型(SS-U)核酸检测试剂盒 PCR-荧光探针法 40头份/盒 24SA-6042猪链球菌通用型(SS-U)核酸检测试剂盒常规PCR40头份/盒 20 SA-6043 猪链球菌Ⅱ型(SS-Ⅱ)核酸检测试剂盒 PCR-荧光探针法 40头份/盒 24SA-6044 猪链球菌Ⅱ型(SS-Ⅱ)核酸检测试剂盒 常规PCR 40头份/盒 2SA-6045 猪链球菌(SS) 基因分型核酸检测试剂盒 多重PCR 10头份/盒 16猪圆环 DNASA-6151 猪圆环病毒(PCV)核酸检测试剂盒 PCR-荧光探针法 40头份/盒 32SA-6152 猪圆环病毒(PCV)核酸检测试剂盒 常规PCR 40头份/盒 28炭疽杆菌 DNASA-6161 炭疽杆菌(BA)核酸检测试剂盒 PCR-荧光探针法 40头份/盒 24SA-6162 炭疽杆菌(BA)核酸检测试剂盒 常规PCR 40头份/盒 20传染病检测试剂盒项目 核酸 种类产品编号产品名称 方 法 规 格 价格艾滋病 RNA SA-2041 人类免疫缺陷(HIV)核酸检测试剂盒 PCR-荧光探针法 40人份/盒 32梅毒 DNA SA-2131 梅毒螺旋体(TP)核酸检测试剂盒 PCR-荧光探针法 40人份/盒 16流感 RNA SA-3051 甲型流感病毒(IAV)核酸检测试剂PCR-荧光探针40人3盒法份/盒 200 SA-3061乙型流感病毒(IBV)核酸检测试剂盒PCR-荧光探针法 40人份/盒 32禽流感 RNA SA-6011禽流感病毒通用型(AIV-U)核酸检测试剂盒PCR-荧光探针法 40人份/盒 32SA-6013禽流感病毒H5亚型(AIV-H5N1)核酸检测试剂盒PCR-荧光探针法 40人份/盒 32SA-6015禽流感病毒H7亚型(AIV-H7)核酸检测试剂盒PCR-荧光探针法 40人份/盒 32SA-6017禽流感病毒H9亚型(AIV-H9)核酸检测试剂盒PCR-荧光探针法 40人份/盒 32SA-6019禽流感病毒(AIV)基因分型核酸检测试剂盒多重RT-PCR 法 10人份/盒 16布氏杆菌 DNASA-6061 布氏杆菌(BS)核酸检测试剂盒PCR-荧光探针法 40人份/盒 24SA-6062 布氏杆菌(BS)核酸检测试剂盒常规PCR 40人份/盒 20狂犬病 RNASA-6121 狂犬病毒(RV)核酸检测试剂盒PCR-荧光探针法 40人份/盒 32SA-6122 狂犬病毒(RV)核酸检测试剂盒RT-PCR 法 40人份/盒 28炭疽 DNA SA-6161 炭疽杆菌(BA)核酸检测试剂盒PCR-荧光探针40人20 0SA-6162 炭疽杆菌(BA)核酸检测试剂盒常规PCR40人份/盒2流行性乙型脑炎RNASA-7011流行性乙型脑炎病毒(JEV)核酸检测试剂盒PCR-荧光探针法40人份/盒320 SA-7012流行性乙型脑炎病毒(JEV)核酸检测试剂盒RT-PCR法40人份/盒28流行性脑脊髓膜炎DNASA-7031脑膜炎奈瑟菌通用型(NM-U)核酸检测试剂盒PCR-荧光探针法40人份/盒240 SA-7032脑膜炎奈瑟菌通用型(NM-U)核酸检测试剂盒常规PCR40人份/盒20 SA-7033脑膜炎奈瑟菌A群(NM-A)核酸检测试剂盒PCR-荧光探针法40人份/盒240 SA-7034脑膜炎奈瑟菌A群(NM-A)核酸检测试剂盒常规PCR40人份/盒20 SA-7035脑膜炎奈瑟菌C群(NM-C)核酸检测试剂盒PCR-荧光探针法40人份/盒240 SA-7036脑膜炎奈瑟菌C群(NM-C)核酸检测试剂盒常规PCR40人份/盒2肺结核DNA SA-3011 结核杆菌(TB)核酸检测试剂盒PCR-荧光探针法40人份/盒16手足口病 RNA SA-7181 肠道病毒EV71核酸检测试剂盒PCR-荧光探针40人300 SA-7182 肠道病毒EV71核酸检测试剂盒 RT-PCR 法40人份/盒 28SA-7185肠道病毒通用型(EV-U)核酸检测试剂盒 PCR-荧光探针法40人份/盒 32SA-7191柯萨奇病毒A16型(CAV-16)核酸检测试剂盒 PCR-荧光探针法40人份/盒 28SA-7192柯萨奇病毒A16型(CAV-16)核酸检测试剂盒RT-PCR 法40人份/盒 32SA-7183肠道病毒EV71/柯萨奇病毒A16型双色荧光检测试剂盒 多重PCR-荧光探针法 40人份/盒 36SA-7187 肠道病毒通用型/肠道病毒EV71/柯萨奇病毒A16型三色荧光检测试剂盒多重PCR-荧光探针法40人份/盒 36登革热 RNASA-7041 登革热病毒(DFV)核酸检测试剂盒PCR-荧光探针法40人份/盒 32SA-7042 登革热病毒(DFV)核酸检测试剂盒 RT-PCR 法40人份/盒 28霍乱 DNASA-7061 霍乱弧菌(VC)核酸检测试剂盒PCR-荧光探针法40人份/盒 24SA-7062 霍乱弧菌(VC)核酸检测试剂盒常规PCR40人份/盒 20临床检测试剂盒产品编号核酸种类 产品名称 方 法规 格 价 格SA-1021 DNA乙型肝炎病毒(HBV)核酸检测试剂盒PCR-荧光探针法40人份/盒 16SA-2011 DNA 沙眼衣原体(CT)核酸检测试剂盒PCR-荧光探针法40人份/盒 16SA-2021 DNA 解脲脲原体(UU)核酸检测试剂盒PCR-荧光探针法40人份/盒 16SA-2031 DNA 淋球菌(NG)核酸检测试剂盒PCR-荧光探针法40人份/盒 16SA-2061 DNA单纯疱疹病毒通用型(HSV-U)核酸检测试剂盒 PCR-荧光探针法40人份/盒 16SA-2051 DNA单纯疱疹病毒II 型(HSV-II)核酸检测试剂盒 PCR-荧光探针法40人份/盒 16SA-2071 DNA人乳头瘤病毒6,11型(HPV-6,11)核酸检测试剂盒 PCR-荧光探针法40人份/盒 16SA-2081 DNA人乳头瘤病毒16,18型(HPV-16,18)核酸检测试剂盒 PCR-荧光探针法40人份/盒 16SA-2091 DNA人乳头瘤病毒高危型(HR-HPV)核酸检测试剂盒 PCR-荧光探针法40人份/盒 16SA-2101 DNA 人巨细胞病毒(HCMV)核酸检测试剂盒PCR-荧光探针法40人份/盒 16SA-2111 DNA 白色念珠菌(CA)核酸检测试剂盒PCR-荧光探针法40人份/盒 6SA-2121 DNA生殖道支原体通用型(MG-U)核酸检测试剂盒 PCR-荧光探针法40人份/盒 16SA-2141 DNA 弓形虫(TOX)核酸检测试剂盒PCR-荧光探针法40人份/盒 16SA-3071 DNA EB 病毒(EBV)核酸检测试剂盒PCR-荧光探针法40人份/盒 16SA-3021 DNA 肺炎支原体(MP)核酸检测试剂盒PCR-荧光探针法40人份/盒 16SA-A04 DNA 人类白细胞抗原(HLA-B27)核酸检测试剂盒 常规PCR40人份/盒 20SA-1011 RNA 甲型肝炎病毒(HAV)核酸检测试剂盒PCR-荧光探针法40人份/盒 32SA-1031 RNA 丙型肝炎病毒(HCV)核酸检测试剂盒PCR-荧光探针法40人份/盒 32SA-1041 RNA 庚型肝炎病毒(HGV)核酸检测试剂盒PCR-荧光探针法40人份/盒 32SA-3031 RNA 呼吸道合胞病毒(RSV)核酸检测试剂盒PCR-荧光探针法40人份/盒 32SA-5011 RNA 白血病融合基因(Bcr-Abl)核酸检测试剂盒PCR-荧光探针法40人份/盒 32SA-5021 RNA 肿瘤多药耐药基因(MDR1)核酸检测试剂盒PCR-荧光探针法40人份/盒 2SA-A03 RNA肿瘤多药耐药基因(MDR1)甲基化核酸检测试剂盒常规PCR40人份/盒 32SA-5031 RNA肿瘤多药耐药相关蛋白基因(MRP1)核酸检测试剂盒 PCR-荧光探针法 40人份/盒 32科研试剂盒产品编号产品名称方 法规 格 价 格SA-5041 线粒体DNA(mtDNA)核酸检测试剂盒PCR-荧光探针法40份/盒 48SA-5051凋亡抑制蛋白Survivin 基因核酸检测试剂盒 PCR-荧光探针法40份/盒 48SA-5061 凋亡抑制蛋白Livin 基因核酸检测试剂盒PCR-荧光探针法40份/盒 48SA-5071 细胞色素P450核酸检测试剂盒PCR-荧光探针法40份/盒 48SA-5081 血管生长因子VEGF-c 核酸检测试剂盒PCR-荧光探针法40份/盒 48SA-5091 基质金属蛋白酶MMP-2基因核酸检测试剂盒PCR-荧光探针法40份/盒 48SA-5111 黏附分子CD44核酸检测试剂盒PCR-荧光探针法40份/盒 48SA-5121 黏附分子E-cad核酸检测试剂盒PCR-荧光探针法40份/盒8SA-5131 黏附分子ICAM基因核酸检测试剂盒PCR-荧光探针法40份/盒48SA-5141 脊髓延髓肌肉萎缩症(SBMA)核酸检测试剂盒PCR-PAGE法40份/盒48SA-5151 遗传小脑共济失调(SCA) 核酸检测试剂盒PCR-PAGE法10份/盒32SA-5161 注意缺陷多巴胺D4受体基因多态性核酸检测试剂盒PCR-PAGE法40份/盒48SA-5171 注意缺陷多巴胺载脂蛋白基因多态性核酸检测试剂盒PCR-PAGE法40份/盒48SA-5181 Nucleostemin基因核酸检测试剂盒PCR-荧光探针法40份/盒48SA-5191 人Dectin-1基因核酸检测试剂盒PCR-荧光探针法40份/盒48SA-5201 人β,1-3-半乳糖苷酶(β,1-3GT) 基因核酸检测试剂盒PCR-荧光探针法40份/盒48SA-5211 人Cosmc 基因核酸检测试剂盒PCR-荧光探针法40份/盒48SA-5221 雄激素受体AR基因多态性检测试剂盒PCR-STR法40份/盒48SA-5231 CYP17基因多态性检测试剂盒PCR-RLFP法40份/盒8SA-5241 亚基基四氢还原酶基因MTHFR C677T检测试剂盒PCR-RLFP法40份/盒48SA-5251 E-选择素G98T 基因多态性检测试剂盒PCR-RLFP法40份/盒48SA-5261 E-选择素基因S128R基因多态性检测试剂盒PCR-RLFP法40份/盒48SA-5271 细胞间黏附分子-1基因K469E多态性检测试剂盒PCR-RLFP法40份/盒48SA-5281 IL-6基因174G/C多态性检测试剂盒PCR-RLFP法40份/盒48SA-5291 FGFR3 1138G/A多态性检测试剂盒PCR-RLFP法40份/盒48其他相关试剂产品名称产品编号方法/说明规格价格质粒DNA提取试剂盒SA-TQ1101 滤柱法50T/盒350 SA-TQ1102 滤柱法200T/盒12RNA提取试剂盒SA-TQ1201 滤柱法50T/盒950 SA-TQ1202 滤柱法100T/盒18TrizolSA-TQ1301------50ml 480SA-TQ1302------100ml 850RNA 稳定液 SA-TQ1303 ------100ml 800PCR 产物纯化及DNA 凝胶回收试剂盒SA-TQ1401滤柱法50T/盒400 SA-TQ1402滤柱法100T/盒750 基因组DNA 抽提试剂盒SA-TQ1501 滤柱法50T/盒650 SA-TQ1502滤柱法100T/盒 12SA-TQ1601盐析法50T/盒450 SA-TQ1602 盐析法100T/盒800 简易DNA 提取液 SA-TQ1701 ------1ml 100SA-TQ1702 ------5ml 400SA-TQ1703 ------10ml 750淋巴细胞提取液SA-TQ1801------100ml 120SA-TQ1802------250ml 300红细胞裂解液(DNA和蛋白) SA-TQ1901 ------ 100ml15红细胞裂解液(RNA专用) SA-TQ1902 ------ 100ml18100bp MAKER SA-MK1201 ------ 50次180 SA-MK1202 ------ 100次350 SA-MK1203 ------ 200次68DL2000 MAKER SA-MK1701 ------ 50次180 SA-MK1702 ------ 100次350 SA-MK1703 ------ 200次68一步法RT-PCR试剂盒SA-A0101 ------20T/盒80 SA-A0102 ------40T/盒15逆转录试剂盒SA-A0201 ------20T/盒420 SA-A0202 ------40T/盒8Simple PCR Kit（DNA）SA-A0301 ------20T/盒450 SA-A0302 ------40T/盒8Two-Step SYBR GreenER SA765-100 ------ 100次3FQ-RT -PCR Kit 0SA765-500 ------ 500次1 2 0 0 0SYBR GreenER FQ-PCR SuperMix UniversalS SA762-100 ------ 100次150 SA762-500 ------ 500次60 SA762-02K ------2000次198Taq DNA Polymase SA-A0401-01 5U/ul 250U120 SA-A0401-02 5U/ul 500U220 SA-A0401-03 5U/ul 1000U40 SA-A0401-04 5U/ul 5000U18dNTP(10mM each) SA-A0402 ------ 1ml 1 8 02×Taq PCR MIX SA-A0403-01 含红色燃料1ml180 SA-A0403-04 含红色燃料5ml80 SA-A0403-07 含红色燃料10ml 100 2×Taq PCR MIXSA-A0403-02------ 1ml 180SA-A0403-05------ 5ml 800SA-A0403-08------ 10ml 15002×Taq PCR MIXSA-A0403-03定量 1ml 220SA-A0403-06定量 5ml 850SA-A0403-09定量 10ml 1600M-MLV 逆转录酶SA-A0410-01200U/ul 50ul 450SA-A0410-02200U/ul 100ul 800SA-A0410-03200U/ul 200ul 1500Random Primer SA-A0404 50pmol/ul 100ul 810×TE buffer pH8.0SA-A0405 ------ 500ml 350EB 溶液 SA-A0406 ------ 50ul 5EB 清除剂 SA-QT1001 ------ 100ml 68050×TAE BufferSA-A0407------ 50ml 85×TBE Buffer SA-A0408 ------ 200ml 120DEPC 处理水 SA-A0409------100ml 90技术服务项目方法 / 说明 数量 收费标准 总RNA 抽提 根据不同要求收费50例以下80元/例 50例以上 50元/例 总DNA 抽提 根据不同要求收费50例以下50元/例 50例以上 40元/例 荧光定量PCR 不包括引物及探针合成费用50例以下150元/例 50例以上 100元/例 定性PCR MSP-PCR 收费200元/例50例以下100元/例 50例以上 80元/例 PCR-SSCP 不包括测序费用50例以下100元/例 50例以上 80元/例 PCR-RFLP 不包括内切酶的费用50例以下100元/例 50例以上 80元/例 PCR-DHPLC ------50例以下200元/例 50例以上 150元/例 逆转录反应 ------50例以下50元/例 50例以上40元/例 PCR-SSP 不包括试剂盒的费用 ------1000元/ 96T/板载体构建片段如大于500bp，则按1000元/例收费50例以下500元/例50例以上1000元/例DNA测序PCR产物另加10元/个纯化费50例以下80元/例50例以上60元/例ELISA检测不包括试剂盒的费用50例以下1500元/48T/板50例以上2000元/96T/板组织细胞分离培养------ ------ 500元/例Westen blot 最低3500元/张膜 (不包抗体) 50例以下300元/例50例以上200元/例流式细胞仪检测不包抗体等标记50例以下50元/例50例以上30元/例生化检测不包括试剂盒的费用50例以下80元/例50例以上60元/例激光共聚焦检测------ 50例以下500元/例50例以上300元/例外周血淋巴细胞分离Ficoll法50例以下50元/例50例以上40元/例T、B、PBM等细胞分离(磁珠法)50例以下500元/例50例以上400元/例MTT ------ 50例以下1500元/48T/板50例以上2000元/96T/板电镜检测------ 50例以下500元/例50例以上400元/例凋亡检测Tunel法50例以下1500元/48T/板50例以上2000元/48T/板Hoechst 33258染色法50例以下300元/例50例以上250元/例DNA Ladder法50例以下100元/例50例以上80元/例微生物培养分离鉴定不包括试剂盒的费用50例以下100元/例50例以上80元/例微生物药敏实验不包括试剂盒的费用50例以下100元/例50例以上80元/例药物浓度检测------50例以下500元/例50例以上400元/例HPLC法50例以下800元/例50例以上600元/例蛋白质双向电泳------ 50例以下5000元/例50例以上4000元/例蛋白纯化过柱法50例以下500元/例50例以上400元/例HPLC法50例以下800元/例50例以上600元/例蛋白质质谱分析------ 50例以下5000元/例50例以上4000元/例荧光显微镜------ ------ 100元/小时肿瘤药敏实验标本新鲜，最低3000元/例------ 800元/种药物基因芯片分析------ ------ 价格面议核酸诊断试剂盒开发------ ------ 价格面议代理产品产品名称产品编号产地规格价格封闭抗体(APLA) ELISA检测试剂盒SA-FBKT001 原装进口50T/盒80 SA-FBKT002 原装进口100T/盒13ABDR SSP 2x96 TypingKit高通量33200-2.1 美国TBG 40T30 33200-2.2 美国TBG 20T15FK506（普乐可复）药物浓度ELISA检测试剂盒SA-S32400 原装进口96T58封闭抗体分析系统SA-ELX800NB 国产套9 8 0 0 0酶标仪ELX800NB 美国Bio-Tek 台7 8 0 0 0基因扩增仪-48孔*0.2ml(热盖) DTC-3E 国产台48微量荧光检测仪-单孔TL998A 国产套6 8 0 0 0实时荧光定量PCR仪-48孔*0.2ml TL988F 国产套3琼脂糖水平电泳槽DYCP-31E 北京六一厂台2 2 0 0凝胶成像系统WD-9413A 北京六一厂套6 9 0 0 0生物安全柜BSC-1500II A2-X 济南鑫贝西台9 8 0罗氏PCR反应管MB068 国产96/盒3 8 0。
中华人民共和国农业部公告第2219号-中华人民共和国农业部公告第2219号
中华人民共和国农业部公告第2219号正文：----------------------------------------------------------------------------------------------------------------------------------------------------中华人民共和国农业部公告第2219号根据《兽药管理条例》和《兽药注册办法》规定，经审核，批准西班牙海博莱生物大药厂生产的氟苯尼考注射液在我国注册，核发《进口兽药注册证书》，并发布产品质量标准、说明书和标签，自发布之日起执行。
批准美国爱德士生物科技有限公司等2家公司生产的鸡传染性支气管炎病毒ELISA抗体检测试剂盒等2种兽药产品在我国再注册，核发《进口兽药注册证书》，并发布修订后的产品质量标准、说明书和标签，自发布之日起执行。
此前发布的同品种兽药产品质量标准同时废止。
批准英国安德国际有限公司(杜邦子公司)生产的过硫酸氢钾复合物粉兽药产品在我国变更注册。
特此公告。
附件：1.进口兽药注册目录2.质量标准3.说明书和标签农业部2015年1月27日附件1进口兽药注册目录兽药名称生产厂名称证书号有效期限备注氟苯尼考注射液Florfenicol Injection西班牙海博莱生物大药厂Laboratorios HIPRA S.A.（2015）外兽药证字01号2015.01-2019.12注册鸡传染性支气管炎病毒ELISA抗体检测试剂盒Infectious Bronchitis Virus ELISA Antibody Test Kit 美国爱德士生物科技有限公司IDEXX Laboratories, Inc.（2015）外兽药证字02号2015.01-2019.12再注册伊维菌素注射液Ivermectin Injection梅里亚有限公司巴西生产厂Merial Saude Animal Ltda（2015）外兽药证字03号2015.01-2019.12再注册过硫酸氢钾复合物粉Compound Peroxymonosulphate Powder（Virkon S）英国安德国际有限公司(杜邦子公司)Antec International Limited(A DuPontCompany)（2010）外兽药证字50号2010.11-2015.10变更注册：增加包装规格1kg/桶、10kg/桶附件2（略）附件3：氟苯尼考注射液等3种兽药产品说明书和标签一、氟苯尼考注射液说明书和标签（一）氟苯尼考注射液说明书【兽药名称】通用名：氟苯尼考注射液商品名：喜乐坦英文名：Florfenicol Injection汉语拼音：Fubennikao Zhusheye【主要成分】氟苯尼考【性状】本品为微黄色的澄明溶液。
安捷伦产品目录
15
Real-Time PCR
16
Mx3000P QPCR System
17
Brilliant III Ultra-Fast SYBR Green QPCR and QRT-PCR Reagents
18
Brilliant III Ultra-Fast QPCR and QRT-PCR Reagents
Agilent / STRATAGENE
Agilent website: /genomics
Welgene | Agilent Stratagene
威健股份有限公司 | Stratagene 總代理
Table of Content
Table of Contents
/ XL1-Red Competent Cells SoloPack Gold Supercompetent Cells
/ TK Competent Cells Specialty Cells
/ Classic Cells / Fine Chemicals For Competent Cells
適用於 UNG 去汙染或 bisulphite
sequencing
適用於 TA Cloning
最高敏感性
取代傳統 Taq 的好選擇
-
2
威健股份有限公司 | Stratagene 總代理
PCR Enzyme & Instrument
Agilent SureCycler 8800
市場上領先的 cycling 速度和 sample 體積 10 ～ 100 μL 簡易快速可以選擇 96 well 和 384 well 操作盤 優秀的溫控設備讓各個 well 都能保持溫度的穩定 七吋的高解析度觸控螢幕讓操作上更為簡便 可以透過網路遠端操控儀器及監控儀器 Agilent 專業的技術支援可以幫助您應對各種 PCR 的問題
管理技术-林荣瑞
无菌检查培养基．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．36 微生物限度检查培养基．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．36 抑菌剂效力检查培养基．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．37 青霉素酶制备培养基．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．38 抗生素检定培养基．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．38 支原检测培养基．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．39 l 美国药典培养基（USP 标准） ．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．49 l 欧洲药典培养基（EP 标准）．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．40 u 临床检验系列．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．42 u 军团菌检测培养基系列．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．44 u 菌种保存和样品运输培养基．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．45 u 其它菌检测培养基．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．45 l 维生素微生物方法检测培养基．． ． ． ． ． ．．．． ．．．．．．．．．．．．．．．．．．．46 l 微生物菌肥检测培养基 ．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．46 l 其他培养基 ．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．46 u 原材料系列．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．48 u 微生物学试验配套试剂．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．49 u 植物组织培养基．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．50 u 细菌生化鉴定管 ．．．．．． ．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．51 l 大肠杆菌生化鉴定管．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．51 l 沙门氏菌生化鉴定管．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．51 l 志贺氏菌生化鉴定管．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．51 l 大肠杆菌 O157 生化鉴定管 ．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．52 l 单增李斯特氏菌生化鉴定管．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．52 l 副溶血性弧菌生化鉴定管．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．53 l 霍乱弧菌生化鉴定管．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．53 l 蜡样芽孢杆菌生化鉴定管．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．54 l 乳酸菌生化鉴定管 GB 标准 ．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．54 l 阪崎杆菌生化鉴定管 GB 标准 ．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．54 u 微生物成套生化鉴定管．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．55 u 培养基添加剂用量表．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．．57
头孢羟氨苄干混悬质量标准USP
Cefadroxil for Oral Suspension USP 250 mg/5 mL and 500 mg/5 mLRx onlyTo reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil for oral suspension and other antibacterial drugs, cefadroxil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Cefadroxil monohydrate is a semisynthetic cephalosporin antibiotic intended for oral administration. It is a white to yellowish-white crystalline powder. It is soluble in water and it is acid-stable. It is chemically designated as 5-Thia-1-azabicyclo[4.2.O]oct-2-ene2-carboxylic acid, 7-[[amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-, monohydrate, [6R-[6α,7β(R*)]]-. It has the formula C16H17N3O5S•H2O and the molecular weight of 381.40. It has the following structural formula:COOH HHOONCH3 SC NH2CONH H H. H2OCefadroxil for oral suspension contains cefadroxil monohydrate. After reconstitution, each 5 mL contains cefadroxil monohydrate equivalent to 250 mg or 500 mg of cefadroxil. In addition, cefadroxil for oral suspension contains the following inactive ingredients: colloidal silicon dioxide, FD&C Yellow No. 6, powder flavor orange, powder flavor pineapple, sodium benzoate, sucrose, and xanthan gum. Cefadroxil for oral suspension is a light orange colored powder, forming orange colored suspension on constitution. CLINICAL PHARMACOLOGY Cefadroxil monohydrate is rapidly absorbed after oral administration. Following single doses of 500 mg and 1000 mg, average peak serum concentrations were approximately 16 and 28 mcg/mL, respectively. Measurable levels were present 12 hours after administration. Over 90% of the drug is excreted unchanged in the urine within 24 hours. Peak urine concentrations are approximately 1800 mcg/mL during the period following a single 500-mg oral dose. Increases in dosage generally produce a proportionate increase in cefadroxil monohydrate urinary concentration. The urine antibiotic concentration, following a 1-g dose, was maintained well above the MIC of susceptible urinary pathogens for 20 to 22 hours. Microbiology In vitro tests demonstrate that the cephalosporins are bactericidal because of their inhibition of cell-wall synthesis. Cefadroxil has been shown to be active against the following organisms both in vitro and in clinical infections (see INDICATIONS AND USAGE): Beta-hemolytic streptococci Staphylococci, including penicillinase-producing strains Streptococcus (Diplococcus) pneumoniae Escherichia coliPage 1 of 8Proteus mirabilis Klebsiella species Moraxella (Branhamella) catarrhalis Note: Most strains of Enterococcus faecalis (formerly Streptococcus faecalis) and Enterococcus faecium (formerly Streptococcus faecium) are resistant to cefadroxil monohydrate. It is not active against most strains of Enterobacter species, Morganella morganii (formerly Proteus morganii), and P. vulgaris. It has no activity against Pseudomonas species and Acinetobacter calcoaceticus (formerly Mima and Herellea species). Susceptibility tests: Diffusion techniques The use of antibiotic disk susceptibility test methods which measure zone diameter give an accurate estimation of antibiotic susceptibility. One such standard procedure1 which has been recommended for use with disks to test susceptibility of organisms to cefadroxil uses the cephalosporin class (cephalothin) disk. Interpretation involves the correlation of the diameters obtained in the disk test with the minimum inhibitory concentration (MIC) for cefadroxil. Reports from the laboratory giving results of the standard single-disk susceptibility test with a 30 mcg cephalothin disk should be interpreted according to the following criteria: Zone diameter (mm) ≥ 18 15-17 ≤ 14 Interpretation (S) Susceptible (I) Intermediate (R) ResistantA report of “Susceptible” indicates that the pathogen is likely to be inhibited by generally achievable blood levels. A report of “intermediate susceptible” suggests that the organism would be susceptible if high dosage is used or if the infection is confined to tissue and fluids (e.g., urine) in which high antibiotic levels are attained. A report of “Resistant’’ indicates that achievable concentrations of the antibiotic are unlikely to be inhibitory and other therapy should be selected. Standardized procedures require the use of laboratory control organisms. The 30 mcg cephalothin disk should give the following zone diameters: Organism Staphylococcus aureus ATCC 25923 Escherichia coli ATCC 25922 Zone Diameter (mm) 29–37 17–22Dilution Techniques When using the NCCLS agar dilution or broth dilution (including microdilution) method² or equivalent, a bacterial isolate may be considered susceptible if the MIC (minimum inhibitory concentration) value for cephalothin is 8 mcg/mL or less. Organisms are considered resistant if the MIC is 32 mcg/mL or greater. Organisms with an MIC value of less than 32 mcg/mL but greater than 8 mcg/mL are intermediate. As with standard diffusion methods, dilution procedures require the use of laboratory control organisms. Standard cephalothin powder should give MIC values in the range of 0.12 mcg/mL and 0.5 mcg/mL for Staphylococcus aureus ATCC 29213. For Escherichia coli ATCC 25922, the MIC range should be between 4 mcg/mL and 16 mcg/mL. ForPage 2 of 8Streptococcus faecalis ATCC 29212, the MIC range should be between 8 and 32 mcg/mL. INDICATIONS AND USAGE Cefadroxil for oral suspension is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli, P. mirabilis, and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A betahemolytic streptococci). Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil monohydrate for the prophylaxis of subsequent rheumatic fever are not available. Note: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil for oral suspension and other antibacterial drugs, cefadroxil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CONTRAINDICATIONS Cefadroxil monohydrate is contraindicated in patients with known allergy to the cephalosporin group of antibiotics. WARNINGS BEFORE THERAPY WITH CEFADROXIL MONOHYDRATE IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFADROXIL, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-SENSITIVITY AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. IF AN ALLERGIC REACTION TO CEFADROXIL MONOHYDRATE OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including cefadroxil monohydrate, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.Page 3 of 8CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated. PRECAUTIONS General Cefadroxil monohydrate should be used with caution in the presence of markedly impaired renal function (creatinine clearance rate of less than 50 mL/min/1.73 M²). (See DOSAGE AND ADMINISTRATION.) In patients with known or suspected renal impairment, careful clinical observation and appropriate laboratory studies should be made prior to and during therapy. Prescribing cefadroxil monohydrate in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Prolonged use of cefadroxil monohydrate may result in the overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken. Cefadroxil monohydrate should be prescribed with caution in individuals with history of gastrointestinal disease particularly colitis. Information for Patients Patients should be counseled that antibacterial drugs including cefadroxil for oral suspension should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When cefadroxil for oral suspension is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by cefadroxil for oral suspension or other antibacterial drugs in the future. Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible. Drug/Laboratory Test Interactions Positive direct Coombs’ tests have been reported during treatment with the cephalosporin antibiotics. In hematologic studies or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side or in Coombs’ testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognized that a positive Coombs’ test may be due to the drug. Carcinogenesis, Mutagenesis and Impairment of Fertility No long-term studies have been performed to determine carcinogenic potential. No genetic toxicity tests have been performed.Page 4 of 8Pregnancy: Pregnancy Category B Reproduction studies have been performed in mice and rats at doses up to 11 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to cefadroxil monohydrate. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Labor and Delivery Cefadroxil monohydrate has not been studied for use during labor and delivery. Treatment should only be given if clearly needed. Nursing Mothers Caution should be exercised when cefadroxil monohydrate is administered to a nursing mother. Pediatric Use (See DOSAGE AND ADMINISTRATION.) Geriatric Use Of approximately 650 patients who received cefadroxil for the treatment of urinary tract infections in three clinical trials, 28% were 60 years and older, while 16% were 70 years and older. Of approximately 1000 patients who received cefadroxil for the treatment of skin and skin structure infection in 14 clinical trials, 12% were 60 years and older while 4% were 70 years and over. No overall differences in safety were observed between the elderly patients in these studies and younger patients. Clinical studies of cefadroxil for the treatment of pharyngitis or tonsillitis did not include sufficient numbers of patients 65 years and older to determine whether they respond differently from younger patients. Other reported clinical experience with cefadroxil has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Cefadroxil is substantially excreted by the kidney, and dosage adjustment is indicated for patients with renal impairment (see DOSAGE AND ADMINISTRATION: Renal Impairment). Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. ADVERSE REACTIONS Gastrointestinal Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment (see WARNINGS). Dyspepsia, nausea and vomiting have been reported rarely. Diarrhea has also occurred. Hypersensitivity Allergies (in the form of rash, urticaria, angioedema, and pruritus) have been observed. These reactions usually subsided upon discontinuation of the drug. Anaphylaxis has also been reported. Other Other reactions have included hepatic dysfunction including cholestasis and elevations in serum transaminase, genital pruritus, genital moniliasis, vaginitis, moderate transient neutropenia, fever. Agranulocytosis, thrombocytopenia, idiosyncratic hepatic failure, erythema multiforme, Stevens-Johnson syndrome, serum sickness, and arthralgia have been rarely reported. In addition to the adverse reactions listed above which have been observed in patients treated with cefadroxil, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics:Page 5 of 8Toxic epidermal necrolysis, abdominal pain, superinfection, renal dysfunction, toxic nephropathy, aplastic anemia, hemolytic anemia, hemorrhage, prolonged prothrombin time, positive Coombs’ test, increased BUN, increased creatinine, elevated alkaline phosphatase, elevated aspartate aminotransferase (AST), elevated alanine aminotransferase (ALT), elevated bilirubin, elevated LDH, eosinophilia, pancytopenia, neutropenia. Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment, when the dosage was not reduced (see DOSAGE AND ADMINISTRATION and OVERDOSAGE). If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated. OVERDOSAGE A study of children under six years of age suggested that ingestion of less than 250 mg/ kg of cephalosporins is not associated with significant outcomes. No action is required other than general support and observation. For amounts greater than 250 mg/kg, induce gastric emptying. In five anuric patients, it was demonstrated that an average of 63% of a 1 g oral dose is extracted from the body during a 6–8 hour hemodialysis session. DOSAGE AND ADMINISTRATION Cefadroxil for oral suspension is acid-stable and may be administered orally without regard to meals. Administration with food may be helpful in diminishing potential gastrointestinal complaints occasionally associated with oral cephalosporin therapy. Adults Urinary Tract Infections: For uncomplicated lower urinary tract infections (i.e., cystitis) the usual dosage is 1 or 2 g per day in a single (q.d.) or divided doses (b.i.d.). For all other urinary tract infections the usual dosage is 2 g per day in divided doses (b.i.d.). Skin and Skin Structure Infections: For skin and skin structure infections the usual dosage is 1 g per day in single (q.d.) or divided doses (b.i.d.). Pharyngitis and Tonsillitis: Treatment of group A beta-hemolytic streptococcal pharyngitis and tonsillitis— 1 g per day in single (q.d.) or divided doses (b.i.d.) for 10 days. Children For urinary tract infections, the recommended daily dosage for children is 30 mg/kg/day in divided doses every 12 hours. For pharyngitis, tonsillitis, and impetigo, the recommended daily dosage for children is 30 mg/kg/day in a single dose or in equally divided doses every 12 hours. For other skin and skin structure infections, the recommended daily dosage is 30 mg/kg/day in equally divided doses every 12 hours. In the treatment of beta-hemolytic streptococcal infections, a therapeutic dosage of cefadroxil monohydrate should be administered for at least 10 days.See chart for total daily dosage for children.Page 6 of 8DAILY DOSAGE OF CEFADROXIL FOR ORAL SUSPENSION Child’s Weight 250 mg/5 mL 500 mg/5 mL Lbs kg 10 4.5 ½ tsp 20 9.1 1 tsp 30 13.6 1½ tsp 40 18.2 2 tsp 1 tsp 50 22.7 2½ tsp 1¼ tsp 60 27.3 3 tsp 1½ tsp 70 & above 31.8 + -2 tsp Renal Impairment In patients with renal impairment, the dosage of cefadroxil monohydrate should be adjusted according to creatinine clearance rates to prevent drug accumulation. The following schedule is suggested. In adults, the initial dose is 1000 mg of cefadroxil monohydrate and the maintenance dose (based on the creatinine clearance rate [mL/min/1.73 M²]) is 500 mg at the time intervals listed below. Creatinine Clearance 0-10 mL/min 10-25 mL/min 25-50 mL/min Dosage Interval 36 hours 24 hours 12 hoursPatients with creatinine clearance rates over 50 mL/min may be treated as if they were patients having normal renal function. Bottle Size 100 mL Reconstitution Directions for Oral Suspension Reconstitution Directions Suspend in a total of 67 mL water. Method: Tap bottle lightly to loosen powder. Add 67 mL of water in two portions. Shake well after each addition. Suspend in a total of 51 mL water. Method: Tap bottle lightly to loosen powder. Add 51 mL of water in two portions. Shake well after each addition. Suspend in a total of 34 mL water. Method: Tap bottle lightly to loosen powder. Add 34 mL of water in two portions. Shake well after each addition.75 mL50 mLAfter reconstitution, store in refrigerator. Shake well before using. Keep container tightly closed. Discard unused portion after 14 days.Page 7 of 8HOW SUPPLIED Cefadroxil for oral suspension is orange-pineapple flavored, and is supplied as follows: 250 mg/5 mL NDC 68180-181-01 50 mL Bottle NDC 68180-181-02 100 mL Bottle 500 mg/5 mL NDC 68180-182-01 50 mL Bottle NDC 68180-182-02 75 mL Bottle NDC 68180-182-03 100 mL Bottle Prior to reconstitution: Store at 25°C (77°F); excursions permitted to 15°–30° C (59°– 86° F). [See USP Controlled Room Temperature]. After reconstitution: Store in refrigerator. Shake well before using. Keep containertightly closed. Discard unused portion after 14 days.REFERENCES 1. National Committee for Clinical Laboratory Standards, Approved Standard, Performance Standards for Antimicrobial Disk Susceptibility Test, 4th Edition, Vol. 10 (7): M2-A4, Villanova, PA, April, 1990. 2. National Committee for Clinical Laboratory Standards, Approved Standard: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 2nd Edition, Vol. 10 (8): M7-A2, Villanova, PA, April, 1990. Manufactured by: Lupin Limited Mumbai 400 098 INDIA Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United StatesNovember 2007ID#:213270Page 8 of 8。
抗荧光衰减封片剂(含DAPI)说明书
抗荧光衰减封片剂（含DAPI）说明书货号：S2110规格：5ml/25ml保存：-20℃保存，一年有效。
产品简介：抗荧光衰减封片剂是一种用于减缓荧光衰减的封片试剂。
以甘油为基础，加入抗荧光衰减剂，有强烈的抗荧光衰减作用，用于对荧光组织和细胞样品的封片。
封片后，样品4℃或者-20℃避光可保存2-3周。
本试剂操作简单，在封片时用移液枪滴一滴抗荧光衰减封片液，盖上盖玻片就可以了。
抗荧光衰减封片剂内含DAPI即4',6-二脒基-2-苯基吲哚(4',6-diamidino-2-phenylindole)，是一种能够与DNA强力结合的荧光染料，常用与荧光显微镜观测。
因为DAPI可以透过完整的细胞膜，它可以用于活细胞和固定细胞的染色，显微镜下可以看到显蓝色荧光的细胞。
DAPI和双链DNA结合后，最大激发波长为360nm，最大发射波长为460nm。
使用说明：使用前平衡至室温。
1.贴壁细胞样品：A.染色完毕后，吸尽液体。
B.滴一滴(20-50ul)抗荧光衰减封片液于载玻片上，盖上贴有细胞的盖玻片，让细胞接触封片液，尽量避免气泡。
C.随后即可通过荧光显微镜观察样品。
2.组织切片：A.染色完毕后，吸尽液体。
B.滴一滴(20-50ul)抗荧光衰减封片液于组织切片上，盖上盖玻片，让切片接触封片液，尽量避免气泡。
C.随后即可通过荧光显微镜观察样品。
3.其它样品：其它样品参考细胞样品或组织切片进行操作。
注意事项：1.荧光物质均易发生衰减，染色后的样品宜避光保存。
2.在使用抗衰减封片液的情况下可以减缓衰减，但仍宜尽量避光和尽早拍照。
3.为了您的安全和健康，请穿实验服并戴一次性手套操作。